The Burlingame, California, company said in a statement that Rosalie Sterner presented results of the study on behalf of Dr Saad Kenderian and a research team at Mayo Clinic in Rochester, Minnesota.
The study was conducted using lenzilumab, the company’s anti-GM-CSF (granulocyte-macrophage colony-stimulating factor) monoclonal antibody, and was recently featured on the cover of the February 14 edition of "blood", the journal of the American Society of Hematology.
The biotech’s lenzilumab monoclonal antibody is designed to reduce the sometimes dangerous side-effects associated with a cancer therapy involving altered T cells.
Lenzilumab, used in combination with CAR-T therapy, prevents the onset of cytokine release syndrome and significantly reduces neuroinflammation, may prevent impairment of the blood-brain barrier and significantly reduces the neuroinflammation caused by CAR-T, according to Humanigen.
The team found that the therapy enhanced antitumor activity, improved overall survival and improved durability of response with a reduced rate of relapse observed with GM-CSF neutralization.
Shares of Humanigen were down $0.12 to $1.24 in Friday’s OTC Markets trading.
Contact Dennis Fitzgerald at [email protected]